the levels of total tau decreased and phosphorylated tau remained unchanged. This observation further strengthens the theory of A ␤ pathology preceding tau pathology in AD.
Introduction
Down syndrome (DS) is the most common genetic disorder with mental retardation and is caused by trisomy 21 . By the age of 40, virtually all adults with DS fulfill the neuropathological criteria for Alzheimer's disease (AD) diagnosis [1] [2] [3] , displaying a cortical pathology with abundant senile plaques of aggregated amyloid-␤ (A ␤ ) peptides and neurofibrillary tangles composed of hyperphosphorylated tau [4] . According to the amyloid cascade hypothesis [5] , AD is caused by an abnormal accumulation of A ␤ during life, which leads to plaque formation with neurodegeneration and formation of tangles as downstream events.
The localization of the A ␤ precursor gene -amyloid precursor protein (APP) gene -on chromosome 21 [6] leads to a lifelong overexpression of APP in patients with DS, resulting in an overproduction of A ␤ during life, which probably explains their inevitable AD pathology [7] . The observation of a patient with DS with a partial trisomy 21 lacking the part of the 21q arm containing the APP gene, and who thus did not develop AD [8] , further strengthens the connection between A ␤ formation and AD. It also emphasizes the need for studying young individuals with DS in search of pathogenic mechanisms early in AD.
Measuring how levels of soluble A ␤ peptides in cerebrospinal fluid (CSF), total tau (t-tau) and tau phosphorylated at threonine 181 (p-tau) change over time in very young individuals with DS could help us understand early events in the pathogenesis of AD. Such measurements could also unravel if the constant overproduction of A ␤ expected in individuals with DS could result in the same A ␤ , t-tau and p-tau patterns seen in CSF from elderly individuals with sporadic AD [9, 10] .
In this study, biomarkers of AD were analyzed in longitudinally taken CSF samples from children with DS, with the first sample taken at 8 months of age and the last at 54 months. Levels of A ␤ 1-37/38/39/40 and A ␤ 42 , forming the disease-specific A ␤ pattern [9] , were measured by Western blot. Concentrations of t-tau, p-tau and A ␤ were measured by the xMAP technology. CSF levels of total A ␤ , as well as individual levels of all A ␤ peptides, increased during the first 54 months of life in these patients with DS. Levels of t-tau decreased while levels of p-tau remained unchanged.
Materials and Methods
The present investigation is a substudy of a previously published investigation, in which young patients with DS were treated with growth hormone (GH) for 3 years starting at 6-9 months of age [11] . The local ethics committee at Uppsala University, Uppsala, Sweden, approved the study. The parents gave informed consent for their children to participate in the study, which was conducted according to the provisions of the Helsinki declaration. CSF samples were taken by lumbar puncture at 6-10 months of age (before start of GH treatment), at 20 and 40 months (during GH treatment) and at 53-54 months (1 year after finishing GH treatment), centrifuged to remove cell debris and stored at -80°C until analysis (demographic data in table 1 ). Treatment with GH had a positive effect on statural growth, but neither accelerated head growth nor had any effect on mental or gross motor development. The growth velocity declined after cessation of treatment [11] . Unfortunately, there are no APOE genotypes of the individuals participating in the study. However, for patients with DS no correlation between APOE genotype and A ␤ levels has been observed in earlier studies [12] [13] [14] .
Western blot was performed according to a previously described protocol [9] . The levels of A ␤ 1-42 were also measured with the xMAP technology and the INNO-BIA AlzBio3 kit (Innogenetics) as well as t-tau and p-tau levels, as previously described [15] . Due to limited sample size not all samples were assayed using the xMAP technology.
All statistical procedures were performed using the Statistical Package for the Social Sciences 12.0.1 (SPSS for Windows). The Shapiro-Wilk test was performed to test the distribution of the data. Data were not normally distributed and since there were a limited number of longitudinal samples available from the same individual, the Mann-Whitney U test was used to compare differences between samples taken at the three different time points. Individual A ␤ peptides were expressed as absolute (ng/ml) and relative values (as a percentage of the total A ␤ peptide concentration; A ␤ 1-X %, fractional A ␤ peptide values); p values lower than 0.05 were considered significant. The ratio between A ␤ 1-42 and A ␤ 1-40 was calculated by dividing the level of A ␤ 1-42 in each subject by A ␤ 1-40 and then the ratio was multiplied by 10 [16] .
Results
In the present study, we have investigated AD biomarkers in CSF during early childhood (8- 3 a) , while no change could be observed in levels of p-tau ( fig. 3 b) .
Discussion
With the knowledge of most patients with DS unavoidably becoming AD patients later in life, there has been an interest among AD researchers to use DS as a model in search of mechanisms causing sporadic AD. Therefore, several studies of AD markers, like A ␤ levels in the brain, plasma and CSF, have been published. The present study is the first longitudinal study of A ␤ and tau levels in CSF measured in patients with DS during early childhood. Soluble A ␤ 1-42 in the brain has been demonstrated to be present already from gestational week 21 in DS fetuses, but was undetectable in age-matched controls [17] . The presence of soluble A ␤ 1-42 preceded plaque formation in these DS patients, although the levels were exponentially increased in brains bearing amyloid plaques. A study of A ␤ concentrations in CSF from older DS individuals of different ages showed a decrease in CSF A ␤ between 21 and 61 years of age [18] , similar to the CSF A ␤ decrease observed during the pathogenesis of sporadic AD [19] [20] [21] . A number of studies have been performed in which plasma levels of A ␤ in patients with DS have been investigated. In one study analyzing the levels of A ␤ 1-42 in plasma from fetuses, no difference was observed between fetuses with DS and those with normal karyotype [22] . Regarding adults with DS, several reports demonstrated increased plasma levels of A ␤ 1-40 and A ␤ 1-42 compared to controls [13, 23, 24] .
The amyloid cascade hypothesis is primarily based on findings from familial AD cases where the disease-causing mutations are known to induce an increased A ␤ production. This is further supported by a report demonstrating that a duplication of the APP locus led to AD in [25] . However, there is a lack of evidence demonstrating overproduction of A ␤ in sporadic AD. The AD-specific peptide pattern found in patients with sporadic AD seems to be tightly regulated [9, 26] , but whether there is an A ␤ overproduction or an impaired A ␤ clearance causing the AD-indicative peptide pattern is unknown. In the present study, we found no AD-indicative A ␤ pattern in individuals with DS, even though they are expected to have an overproduction of A ␤ . If this suggests that the elevated A ␤ levels leading to plaque formation in sporadic AD are due to insufficient clearance, rather than overproduction of A ␤ , remains to be elucidated. Decreased levels of A ␤ 1-42 in CSF, measured by ELISA, have been used as a diagnostic marker of sporadic AD [27] and a similar decrease has been repeatedly demonstrated in individuals with DS in their sixth decade, compared to age-matched controls [28] . In addition, an agedependent decrease of ELISA-measured A ␤ 1-42 levels in CSF has been observed in patients with DS between 21 and 61 years of age with the highest levels found in the youngest individual. The concentrations then decreased with age accompanied by an expected acceleration of plaque pathology [18] . This A ␤ 1-42 decrease has been suggested to be due to the accelerated A ␤ accumulation in the brain leading to drainage of A ␤ from CSF with declining A ␤ levels as a consequence. These observations fit well with the results from this study where the patients were followed during their first 4 years of life when deposition of A ␤ into plaques is expected to be low and thus the patients display increasing levels of A ␤ in CSF. There was no indication of a longitudinal decrease in the A ␤ 1-42 /A ␤ 1-40 ratio in these individuals, where a lowering of the ratio is used as a marker of enhanced risk of developing AD [16, 29] . This further emphasizes that studies of A ␤ in CSF during early childhood of patients with DS represent prestages of AD pathology.
There is emerging evidence of oligomeric A ␤ as the toxic molecules involved early in the pathogenesis (reviewed in Walsh and Selkoe [30] ) and oligomeric A ␤ has been shown to exist in CSF [31] [32] [33] . In addition, it has been observed that aggregation of A ␤ into oligomeric and fibrillar species leads to a decline in A ␤ 1-42 levels when measured by ELISA [34] . This makes the observation that A ␤ 1-42 levels measured by Western blot and levels measured by xMAP technology display directly opposite patterns in young individuals with DS very interesting. While Western blot-measured A ␤ 1-42 levels increase over time, xMAP-measured levels decrease ( fig. 2 ) , which could be explained by methodological differences, i.e. while Western blot is a denaturing method, xMAP analysis is made under native conditions. This phenomenon has been observed earlier and has been suggested to be due to epitope masking, caused both by A ␤ aggregation and A ␤ binding to other proteins, leading to underestimated A ␤ levels when performing native analyses [34, 35] . Interestingly, in cell and animal models harboring the aggregation-prone Arctic APP mutation [36] , this divergence in soluble A ␤ levels measured by Western blot and ELISA has been shown to be caused by the formation of soluble A ␤ oligomers [37] . Hence, the observed decrease in the DS infants, measured by the xMAP technology in this study, might be due to the presence of soluble oligomeric A ␤ .
A marked elevation of both t-tau and p-tau in CSF can be used to distinguish sporadic AD cases from healthy individuals [38] and similar elevations of t-tau have been observed in studies of adult DS patients [18, 39] . However, the very young individuals with DS in this study displayed decreased levels of t-tau in CSF during their first 4 years of life ( fig. 3 a) , while levels of p-tau remained virtually unchanged ( fig. 3 b) . Increasing levels of tau in CSF have been shown to correlate with frequency of neurofibrillary tangles in the AD brain [40] , and since the patients with DS in this study were very young and most likely did not have either a cortical A ␤ or tau pathology [17] , increasing levels of tau were not expected. The decreasing levels of tau are not believed to be due to maturation of the blood-brain barrier since the blood-brain barrier is thought to have reached full maturation at birth. Protein levels in CSF, including levels of tau and ptau, during early childhood have not been studied extensively, though there are results indicating that there is an age-dependent change before 3 months of age after which levels become more stable during childhood [41] . Levels of p-tau have been shown to vary during development with decreasing levels with age [41] . The lack of change in the present study may be explained by the relatively short follow-up time. The early overproduction of A ␤ without an increase in p-tau supports the suggestion of A ␤ as the driving force in AD pathology and the hyperphosphorylation of tau, which leads to tangle formation, as a downstream event [42] .
To conclude, children with DS exhibit increasing CSF levels of A ␤ during their first 4 years of life, probably due to the trisomy of APP and low aggregation rate of A ␤ at this early age. The inconsistency of A ␤ 1-42 levels measured by two different methods indicates formation of soluble A ␤ aggregates, oligomers, early in life. The non-AD-indicative A ␤ pattern found could indicate that sporadic AD is caused by an impaired A ␤ clearance, rather than an overproduction of A ␤ ; p-tau and t-tau show no AD-like changes during early childhood, probably due to the lack of neurofibrillary tangle formation in the brain of these young individuals.
